Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Conclusions and Future Perspectives The collective evidence positions incretin receptor agonists as a unique class of drugs with multi-organ anti-fibrotic potential, now extending to fibro-inflammatory diseases like osteoarthritis
But this story is really about something bigger
Cardiologists involved in obesity research have raised particular concern about sympathomimetic-GLP-1 combinations in patients with hypertension, arrhythmia history, or coronary artery disease
Available from: Jett, L., Lger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., van Wyk, P., Pham, K., & Bridon, D
US$ 27.03
US$ 26.88
US$ 29.39
US$ 29.31
US$ 26.43
US$ 23.07
US$ 21.45
